- Policy
- Oxiracetam’s next...ordeal of brain function enhancers
- by Lee, Tak-Sun Aug 9, 2022 05:56am
- It’s a time of ordeal for brain function enhancers. In addition to choline alfoscerate, whose scope of use has been reduced through reimbursement reevaluations, acetyl-L-carnitine failed to demonstrate its efficacy during clinical reevaluations. As a result, acetyl-L-carnitine is expected to completely disappear from the prescrip
- Opinion
- [Reporter's view] COVID-19 vaccination strategy
- by Aug 9, 2022 05:56am
- The MFDS has begun a preliminary review of the vaccine for COVID-19 in Moderna and Pfizer. The preliminary review is to review the submitted clinical data in advance and to quickly determine whether to grant permission when the company applies for an item permit by adding non-clinical and quality data in the future. The divalent vaccine, w
- Company
- Baxter International’s GM Dong-Wook Hyun suddenly resigns
- by Eo, Yun-Ho Aug 9, 2022 05:56am
- Dong-Wook Hyun, General Manager of Baxter International Korea, resigned. According to industry sources, Hyun submitted his letter of resignation last month and left the company. The exact reason for his resignation remains unknown. With Hyun’s resignation, Baxter is now seeking a new head, during which Kwang-hyuk Im, Vice President of
- Policy
- It's hard to prescribe oral medicine for COVID-19
- by Kim, Jung-Ju Aug 9, 2022 05:56am
- Amid the remarkable re-proliferation of COVID-19, the newly proposed National Infectious Disease Crisis Response Advisory Committee advised medical staff to create detailed guidelines for prescriptions in consideration of difficulties in the dispensing process. The National Advisory Committee on Infectious Disease Crisis Response (Chairman
- Company
- Korean companies win first round of Entresto patent suit
- by Kim, Jin-Gu Aug 8, 2022 06:09am
- The first patent dispute over Novartis’s heart failure treatment ‘Entresto (valsartan+ sacubitril) ended with the victory of the Korean generic companies. The exclusive market approval (first generic exclusivity) that received attention is expected to be granted to 10 companies including Hanmi Pharmaceuticals, with the possibility of D
- Company
- Revised guidelines for dyslipidemia in Korea
- by Eo, Yun-Ho Aug 8, 2022 06:09am
- In the management of dyslipidemia, it is believed that drug prescriptions will be more aggressive in Korea. In April, The Korean Society of Lipid and Atherosclerosis unveiled some of the contents of the fifth edition of the 2022 dyslipidemia treatment guidelines at the Spring Conference, and will officially announce it in September. What is n
- Policy
- MFDS beings rolling review of Pfizer’s multivalent vaccine
- by Lee, Hye-Kyung Aug 8, 2022 06:09am
- The Ministry of Food and Drug Safety (Minister: Yu-Kyoung Oh) announced that it had started a rolling review on the clinical trial data that Pfizer Korea submitted on the 5th for its COVID-19 vaccine ‘Comirnaty2 Inj. 0.1mg/mL.' Comirnaty2 Inj. 0.1mg/mL. is a multivalent mRNA vaccine that presents antigens for both the original COVID-19 v
- Policy
- 500 billion won in K-Bio and Vaccine Fund was created
- by Kim, Jung-Ju Aug 8, 2022 06:09am
- The government has finalized a plan to create a K-Bio and Vaccine Fund" worth a total of 500 billion won this year and has started selecting operators. In the future, the government plans to expand the scale to around 1 trillion won. The MOHW (first vice minister Cho Kyu-hong) announced on the 4th that it will report and confirm the plan to c
- Company
- Nabota's sales in US in 1Q of the year were 92 billion won
- by Aug 8, 2022 06:09am
- Daewoong Pharmaceutical's botulinum toxin drug Nabota broke a new quarterly sales record in North America. Sales also improved in the second quarter following the first quarter, surpassing 90 billion won in sales in the first half. Daewoong Pharmaceutical's partner Evolus announced on the 3rd (local time) that its sales of Jubo (Nabota) re
- Policy
- Supply of Children's Tylenol suspension will be normalized
- by Lee, Tak-Sun Aug 7, 2022 11:30pm
- The product license was withdrawn due to the suspension of the operation of the Jansen Hyangnam plant in Korea, but the new product re-licensed due to technology transfer will be listed as starting in August. This includes child Tylenol suspension, and attention is being paid to whether supply and demand will be normalized with new benefits,
